Cargando…

Development of core outcome sets of Food for Special Medical Purposes designed for type 2 diabetes mellitus: a study protocol

BACKGROUND: The Chinese government stipulates all food for special medical purposes (FSMP) designed for specific diseases to be tested in clinical trials before approving it for registration. The process of developing core outcome sets (COSs), the minimum sets of outcomes supposed to be measured and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Dongyu, Gong, Jie, Wei, Yaoyao, Chen, Muxi, Yu, Jiajie, Du, Liang, Hu, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037765/
https://www.ncbi.nlm.nih.gov/pubmed/36959627
http://dx.doi.org/10.1186/s13063-023-07214-2
_version_ 1784911945606889472
author Mu, Dongyu
Gong, Jie
Wei, Yaoyao
Chen, Muxi
Yu, Jiajie
Du, Liang
Hu, Wen
author_facet Mu, Dongyu
Gong, Jie
Wei, Yaoyao
Chen, Muxi
Yu, Jiajie
Du, Liang
Hu, Wen
author_sort Mu, Dongyu
collection PubMed
description BACKGROUND: The Chinese government stipulates all food for special medical purposes (FSMP) designed for specific diseases to be tested in clinical trials before approving it for registration. The process of developing core outcome sets (COSs), the minimum sets of outcomes supposed to be measured and reported, provides an economical and practical option for stakeholders to communicate and cooperate in conducting clinical trials as well as in reporting FSMP outcomes. This study uses type 2 diabetes mellitus (T2DM) as an example to develop COS for clinical trials of FSMP. METHODS: The COS for FSMP-T2DM will be divided into 3 phases and developed following COS-STAP and COS-STAD: (1) Generate a list of relevant outcomes identified from a systematic review, in which information sources will mainly include published studies, regulatory documentation, and qualitative interviews of stakeholders. The identified outcomes will be categorized using a conceptual framework and formatted into the first round of the Delphi survey questionnaire items. (2) At least 2 rounds of Delphi surveys will be performed among stakeholders to create the COS for FSMP-T2DM. Patients, clinical dietitians, physicians, COS researchers, journal editors, FSMP manufacturers, and regulatory representatives will be invited to score each outcome from aspects of importance. (3) Hold a face-to-face or online consensus meeting to refine the content of the COS for FSMP-T2DM. Key stakeholders will be invited to attend the meeting to discuss and agree on the final COS. DISCUSSION: We have prepared an alternative solution of the Likert scale selection, Delphi survey rounds, scoring group, and consensus definitions in case of an unexpected situation. TRIAL REGISTRATION: COMET (1547). Registered on March 23, 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-023-07214-2.
format Online
Article
Text
id pubmed-10037765
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100377652023-03-25 Development of core outcome sets of Food for Special Medical Purposes designed for type 2 diabetes mellitus: a study protocol Mu, Dongyu Gong, Jie Wei, Yaoyao Chen, Muxi Yu, Jiajie Du, Liang Hu, Wen Trials Study Protocol BACKGROUND: The Chinese government stipulates all food for special medical purposes (FSMP) designed for specific diseases to be tested in clinical trials before approving it for registration. The process of developing core outcome sets (COSs), the minimum sets of outcomes supposed to be measured and reported, provides an economical and practical option for stakeholders to communicate and cooperate in conducting clinical trials as well as in reporting FSMP outcomes. This study uses type 2 diabetes mellitus (T2DM) as an example to develop COS for clinical trials of FSMP. METHODS: The COS for FSMP-T2DM will be divided into 3 phases and developed following COS-STAP and COS-STAD: (1) Generate a list of relevant outcomes identified from a systematic review, in which information sources will mainly include published studies, regulatory documentation, and qualitative interviews of stakeholders. The identified outcomes will be categorized using a conceptual framework and formatted into the first round of the Delphi survey questionnaire items. (2) At least 2 rounds of Delphi surveys will be performed among stakeholders to create the COS for FSMP-T2DM. Patients, clinical dietitians, physicians, COS researchers, journal editors, FSMP manufacturers, and regulatory representatives will be invited to score each outcome from aspects of importance. (3) Hold a face-to-face or online consensus meeting to refine the content of the COS for FSMP-T2DM. Key stakeholders will be invited to attend the meeting to discuss and agree on the final COS. DISCUSSION: We have prepared an alternative solution of the Likert scale selection, Delphi survey rounds, scoring group, and consensus definitions in case of an unexpected situation. TRIAL REGISTRATION: COMET (1547). Registered on March 23, 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-023-07214-2. BioMed Central 2023-03-24 /pmc/articles/PMC10037765/ /pubmed/36959627 http://dx.doi.org/10.1186/s13063-023-07214-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Mu, Dongyu
Gong, Jie
Wei, Yaoyao
Chen, Muxi
Yu, Jiajie
Du, Liang
Hu, Wen
Development of core outcome sets of Food for Special Medical Purposes designed for type 2 diabetes mellitus: a study protocol
title Development of core outcome sets of Food for Special Medical Purposes designed for type 2 diabetes mellitus: a study protocol
title_full Development of core outcome sets of Food for Special Medical Purposes designed for type 2 diabetes mellitus: a study protocol
title_fullStr Development of core outcome sets of Food for Special Medical Purposes designed for type 2 diabetes mellitus: a study protocol
title_full_unstemmed Development of core outcome sets of Food for Special Medical Purposes designed for type 2 diabetes mellitus: a study protocol
title_short Development of core outcome sets of Food for Special Medical Purposes designed for type 2 diabetes mellitus: a study protocol
title_sort development of core outcome sets of food for special medical purposes designed for type 2 diabetes mellitus: a study protocol
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037765/
https://www.ncbi.nlm.nih.gov/pubmed/36959627
http://dx.doi.org/10.1186/s13063-023-07214-2
work_keys_str_mv AT mudongyu developmentofcoreoutcomesetsoffoodforspecialmedicalpurposesdesignedfortype2diabetesmellitusastudyprotocol
AT gongjie developmentofcoreoutcomesetsoffoodforspecialmedicalpurposesdesignedfortype2diabetesmellitusastudyprotocol
AT weiyaoyao developmentofcoreoutcomesetsoffoodforspecialmedicalpurposesdesignedfortype2diabetesmellitusastudyprotocol
AT chenmuxi developmentofcoreoutcomesetsoffoodforspecialmedicalpurposesdesignedfortype2diabetesmellitusastudyprotocol
AT yujiajie developmentofcoreoutcomesetsoffoodforspecialmedicalpurposesdesignedfortype2diabetesmellitusastudyprotocol
AT duliang developmentofcoreoutcomesetsoffoodforspecialmedicalpurposesdesignedfortype2diabetesmellitusastudyprotocol
AT huwen developmentofcoreoutcomesetsoffoodforspecialmedicalpurposesdesignedfortype2diabetesmellitusastudyprotocol